IS6798A - Atorvastatínhálfkalsíum form VII - Google Patents

Atorvastatínhálfkalsíum form VII

Info

Publication number
IS6798A
IS6798A IS6798A IS6798A IS6798A IS 6798 A IS6798 A IS 6798A IS 6798 A IS6798 A IS 6798A IS 6798 A IS6798 A IS 6798A IS 6798 A IS6798 A IS 6798A
Authority
IS
Iceland
Prior art keywords
form vii
calcium form
atorvastatin semi
atorvastatin
semi
Prior art date
Application number
IS6798A
Other languages
English (en)
Inventor
Aronhime Judith
Lidor-Hadas Ramy
Niddam Valerie
Lifshitz Revital
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of IS6798A publication Critical patent/IS6798A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
IS6798A 2000-11-03 2003-04-30 Atorvastatínhálfkalsíum form VII IS6798A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24589700P 2000-11-03 2000-11-03
PCT/US2001/043947 WO2002041834A2 (en) 2000-11-03 2001-11-05 Atorvastatin hemi-calcium form vii

Publications (1)

Publication Number Publication Date
IS6798A true IS6798A (is) 2003-04-30

Family

ID=22928549

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6798A IS6798A (is) 2000-11-03 2003-04-30 Atorvastatínhálfkalsíum form VII

Country Status (18)

Country Link
US (1) US6605636B2 (is)
EP (1) EP1332130A4 (is)
JP (1) JP2004513956A (is)
KR (1) KR100704213B1 (is)
CN (1) CN1535139A (is)
AU (1) AU4150602A (is)
CA (1) CA2426632C (is)
CZ (1) CZ20031495A3 (is)
HR (1) HRP20030442A2 (is)
HU (1) HUP0303765A2 (is)
IL (2) IL155734A0 (is)
IS (1) IS6798A (is)
MX (1) MXPA03003900A (is)
NO (1) NO20031986D0 (is)
PL (1) PL362472A1 (is)
SK (1) SK6592003A3 (is)
WO (1) WO2002041834A2 (is)
ZA (1) ZA200303972B (is)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
HUP0302519A3 (en) * 2000-12-27 2008-10-28 Teva Pharma Crystalline forms of atorvastatin, process for their preparation and pharmaceutical compositions containing them
UA74075C2 (en) * 2001-06-29 2005-10-17 Warner Lambert Co NOVEL CRYSTALLINE FORMS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-b, d-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1??-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1)(ATORVASTATIN) (VARIANTS)
JP2005500351A (ja) * 2001-07-30 2005-01-06 ドクター・レディーズ・ラボラトリーズ・リミテッド 結晶形態ｖｉおよびｖｉｉのアトルバスタチンカルシウム
US7074818B2 (en) 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
US20060020137A1 (en) * 2001-11-29 2006-01-26 Limor Tessler Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
EP1480950A4 (en) * 2002-02-15 2005-05-18 Teva Pharma NOVEL HEMI-CALCIUM CRYSTALLINE FORMS OF ATORVASTATIN AND METHODS FOR THEIR PREPARATION, AS WELL AS NEW METHODS FOR THE PREPARATION OF FORORVASTATIN HEMI-CALCIUM FORMS I, VIII AND IX
CA2475123A1 (en) * 2002-02-19 2003-08-28 Teva Pharmaceutical Industries Ltd. Desolvating solvates of atorvastatin hemi-calcium
EP1572643A2 (en) * 2002-11-28 2005-09-14 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
FR2849029B1 (fr) 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
EP1614412A1 (de) * 2003-11-18 2006-01-11 Helm AG Verfahren zur Herstellung von freifliessenden, pulverförmigen Atorvastatin-Adsorbaten
WO2005090301A1 (en) * 2004-03-17 2005-09-29 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
CA2627940A1 (en) 2004-03-17 2005-10-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
ES2739493T3 (es) 2004-05-05 2020-01-31 Pfizer Prod Inc Formas de sal de de atorvastatina con benetamina
AU2005263550C1 (en) * 2004-07-16 2013-01-17 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
EP1771412A2 (en) 2004-07-20 2007-04-11 Warner-Lambert Company LLC Crystalline forms of [r-(r*)]-2-(4-fluorophenyl)-bet a,gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid calcium salt (2:1)
TWI321132B (en) * 2004-09-28 2010-03-01 Teva Pharma Process for preparing forms of atorvastatin calcium substantially free of impurities
MX2007004425A (es) * 2004-10-18 2007-06-07 Teva Pharma Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente.
CN101048141A (zh) 2004-10-28 2007-10-03 沃尼尔·朗伯有限责任公司 形成非晶形的阿托伐他汀的方法
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
WO2006106372A1 (en) * 2005-04-08 2006-10-12 EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság New crystalline atorvastatin hemicalcium salt polymorph form
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
CA2628666A1 (en) * 2005-11-21 2007-05-24 Teva Pharmaceutical Industries Ltd. Atorvastatin formulation
US8084488B2 (en) * 2005-11-21 2011-12-27 Pfizer Inc. Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
TW200745026A (en) 2005-12-13 2007-12-16 Teva Pharma Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
EP1877375A1 (en) * 2006-03-01 2008-01-16 Teva Pharmaceutical Industries Ltd Process for preparing a crystalline form of atorvastatin hemi-calcium
BRPI0702900A2 (pt) * 2006-06-28 2011-03-15 Teva Pharma formas cristalinas da atorvastatina
US9334266B2 (en) 2009-09-04 2016-05-10 The University Of Toledo Catalysts and related processes for producing optically pure beta-lactones from aldehydes and compositions produced thereby
KR20120011249A (ko) * 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CR20200220A (es) 2013-11-15 2020-11-18 Akebia Therapeutics Inc FORMAS SÓLIDAS DE ÁCIDO {[5-(3-CLOROFENIL)-3-HIDROXIPIRIDIN-2-CARBONIL]AMINO}ACÉTICO, COMPOSICIONES, Y USOS DE LAS MISMAS (Divisional 2016-0222)
KR101720894B1 (ko) 2016-01-05 2017-03-30 김상우 무좀치료에 도움을 주는 건식 족욕기

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
SI0848705T1 (en) 1995-07-17 2002-04-30 Warner-Lambert Company Crystalline r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
ES2349364T3 (es) 1999-11-17 2010-12-30 Teva Pharmaceutical Industries, Ltd. Procedimiento para la preparación de una forma polimórfica de atorvastatina cálcica.
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
HUP0302519A3 (en) * 2000-12-27 2008-10-28 Teva Pharma Crystalline forms of atorvastatin, process for their preparation and pharmaceutical compositions containing them
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
UA74075C2 (en) * 2001-06-29 2005-10-17 Warner Lambert Co NOVEL CRYSTALLINE FORMS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-b, d-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1??-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1)(ATORVASTATIN) (VARIANTS)
JP2005500351A (ja) * 2001-07-30 2005-01-06 ドクター・レディーズ・ラボラトリーズ・リミテッド 結晶形態ｖｉおよびｖｉｉのアトルバスタチンカルシウム

Also Published As

Publication number Publication date
CZ20031495A3 (cs) 2004-01-14
EP1332130A2 (en) 2003-08-06
US20020115709A1 (en) 2002-08-22
KR20040005854A (ko) 2004-01-16
IL155734A (en) 2008-11-26
HUP0303765A2 (hu) 2004-03-01
NO20031986L (no) 2003-05-02
JP2004513956A (ja) 2004-05-13
US6605636B2 (en) 2003-08-12
WO2002041834A3 (en) 2002-07-18
CN1535139A (zh) 2004-10-06
IL155734A0 (en) 2003-11-23
SK6592003A3 (en) 2004-01-08
PL362472A1 (en) 2004-11-02
WO2002041834A2 (en) 2002-05-30
NO20031986D0 (no) 2003-05-02
EP1332130A4 (en) 2004-01-21
MXPA03003900A (es) 2005-02-17
KR100704213B1 (ko) 2007-04-10
HRP20030442A2 (en) 2005-06-30
ZA200303972B (en) 2004-08-23
WO2002041834A8 (en) 2003-01-03
CA2426632C (en) 2008-08-05
CA2426632A1 (en) 2002-05-30
AU4150602A (en) 2002-06-03

Similar Documents

Publication Publication Date Title
IS6798A (is) Atorvastatínhálfkalsíum form VII
DZ3409A1 (fr) Association therapeuthique
ATE290000T1 (de) Muscarinagonisten
ATE252099T1 (de) Biarylcarboxamide
NO20010834L (no) Flerbruks-rörfrakoblingsanordning
DE10136334B8 (de) Hochgeschwindigkeitsvertikalresonatoroberflächenemissionslaser
DE60112185D1 (de) Signalartbestimmung
ATE312098T1 (de) Thiazinoxazolidinon
ATA2932001A (de) Schneefräse
DE60125415D1 (de) Formeinsatz
EE05197B1 (et) Linesoliid - kristallivorm II
DE50100710D1 (de) Wischblatt
ATE298751T1 (de) 7-oxopyridoryrimidine
ATE262530T1 (de) Indolochinazolinone
DE1274523T1 (de) Hochdruckumformspülanlage
DE10192638T1 (de) Bohrstangenladevorrichtung
AR028336A1 (es) 4-hidroxi-tetrahidropiridonas fenilsubstituidas
ATE509008T1 (de) Sulfonylguanidine
DE10196064T1 (de) Halbleiterfotodektionsgerät
DE50100817D1 (de) Kugelgelenk
DE50011511D1 (de) Blowby-Heizung
DE10052925B4 (de) Schaukelbett
ATE476423T1 (de) Benzoylpyridazine
DE50007634D1 (de) Kardioplegieballonkatheter
DE10085445T1 (de) Drahterodierbearbeitungseinrichtung